TY - JOUR
T1 - Implementation of a Human Renal Proximal Tubule on a Chip for Nephrotoxicity and Drug Interaction Studies
AU - Vormann, Marianne K.
AU - Vriend, Jelle
AU - Lanz, Henriëtte L.
AU - Gijzen, Linda
AU - van den Heuvel, Angelique
AU - Hutter, Simon
AU - Joore, Jos
AU - Trietsch, Sebastiaan J.
AU - Stuut, Christiaan
AU - Nieskens, Tom T.G.
AU - Peters, Janny G.P.
AU - Ramp, Daniela
AU - Caj, Michaela
AU - Russel, Frans G.M.
AU - Jacobsen, Björn
AU - Roth, Adrian
AU - Lu, Shuyan
AU - Polli, Joseph W.
AU - Naidoo, Anita A.
AU - Vulto, Paul
AU - Masereeuw, Rosalinde
AU - Wilmer, Martijn J.
AU - Suter-Dick, Laura
N1 - Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2021/4
Y1 - 2021/4
N2 - Proximal tubule epithelial cells (PTEC) are susceptible to drug-induced kidney injury (DIKI). Cell-based, two-dimensional (2D) in vitro PTEC models are often poor predictors of DIKI, probably due to the lack of physiological architecture and flow. Here, we assessed a high throughput, 3D microfluidic platform (Nephroscreen) for the detection of DIKI in pharmaceutical development. This system was established with four model nephrotoxic drugs (cisplatin, tenofovir, tobramycin and cyclosporin A) and tested with eight pharmaceutical compounds. Measured parameters included cell viability, release of lactate dehydrogenase (LDH) and N-acetyl-β-D-glucosaminidase (NAG), barrier integrity, release of specific miRNAs, and gene expression of toxicity markers. Drug-transporter interactions for P-gp and MRP2/4 were also determined. The most predictive read outs for DIKI were a combination of cell viability, LDH and miRNA release. In conclusion, Nephroscreen detected DIKI in a robust manner, is compatible with automated pipetting, proved to be amenable to long-term experiments, and was easily transferred between laboratories. This proof-of-concept-study demonstrated the usability and reproducibility of Nephroscreen for the detection of DIKI and drug-transporter interactions. Nephroscreen it represents a valuable tool towards replacing animal testing and supporting the 3Rs (Reduce, Refine and Replace animal experimentation).
AB - Proximal tubule epithelial cells (PTEC) are susceptible to drug-induced kidney injury (DIKI). Cell-based, two-dimensional (2D) in vitro PTEC models are often poor predictors of DIKI, probably due to the lack of physiological architecture and flow. Here, we assessed a high throughput, 3D microfluidic platform (Nephroscreen) for the detection of DIKI in pharmaceutical development. This system was established with four model nephrotoxic drugs (cisplatin, tenofovir, tobramycin and cyclosporin A) and tested with eight pharmaceutical compounds. Measured parameters included cell viability, release of lactate dehydrogenase (LDH) and N-acetyl-β-D-glucosaminidase (NAG), barrier integrity, release of specific miRNAs, and gene expression of toxicity markers. Drug-transporter interactions for P-gp and MRP2/4 were also determined. The most predictive read outs for DIKI were a combination of cell viability, LDH and miRNA release. In conclusion, Nephroscreen detected DIKI in a robust manner, is compatible with automated pipetting, proved to be amenable to long-term experiments, and was easily transferred between laboratories. This proof-of-concept-study demonstrated the usability and reproducibility of Nephroscreen for the detection of DIKI and drug-transporter interactions. Nephroscreen it represents a valuable tool towards replacing animal testing and supporting the 3Rs (Reduce, Refine and Replace animal experimentation).
KW - Drug-screening
KW - Drug-transporter interaction
KW - Microfluidics
KW - miRNA
KW - Pharmaceutical
KW - Renal-proximal-tubule-on-a-chip
UR - http://www.scopus.com/inward/record.url?scp=85101384155&partnerID=8YFLogxK
U2 - 10.1016/j.xphs.2021.01.028
DO - 10.1016/j.xphs.2021.01.028
M3 - Article
C2 - 33545187
AN - SCOPUS:85101384155
SN - 0022-3549
VL - 110
SP - 1601
EP - 1614
JO - Journal of Pharmaceutical Sciences
JF - Journal of Pharmaceutical Sciences
IS - 4
ER -